|Awarded On||August 18, 2021|
|Title||Protein Degradation of CDK9 for Treatment of Drug-Resistant Mantle Cell Lymphoma|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Medical Branch at Galveston|
|Principal Investigator/Program Director||Jia Zhou|
*Pending contract negotiation
Mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell lymphoma, shows a high possibility for disease progression and relapse even after complete remission with the current frontline therapies such as ibrutinib, venetoclax and more recently CAR T therapy approved by FDA with clinical trials led by Dr. Wang (co-PI in this proposal). Once relapsed, the patients will face more aggressive disease that requires immediate alternative therapies to overcome the resistance. Developing novel therapeutic approaches to overcome drug-resistance in MCL thus represents an unmet medical need. Inspired by our recent advances in translational and preclinical studies and the initiation of ph...